Japan stem cells

Weekend reads: stem cells, CRISPR, glioma, stroke, RTT & more

Venkatesh-et-al.-Nature-2019-Fig-2e

Every so often I realize I’ve accumulated a bunch of tabs on my browsers of things I need to dive into as time permits, which sometimes translates into a collection of recommended reads here on The Niche. Here are some recommended recent reads in the stem cell/regenerative medicine field and childhood cancer space. It includes …

Weekend reads: stem cells, CRISPR, glioma, stroke, RTT & more Read More »

Japan stem cell clinical studies rapidly piling up

Shibata-et-al.-Cell-reports-2018-corneal-structures-made-from-hIPSCs

Japan is a leader in stem cell and regenerative medicine research, and in particular in clinical translation toward the bedside. Induced pluripotent stem cell (IPSC)-based investigational therapies are rightly an area of focus in Japan given their invention by Nobel Laureate Shinya Yamanaka. Small clinical studies based on IPSC have been initiated there for several …

Japan stem cell clinical studies rapidly piling up Read More »

Japan’s dangerous gamble approving unproven stem cells for spinal cord injury

spinal-cord-injury-MRI

There is real hope for treating spinal cord injury with stem cell-based therapies in the future. However, unfortunately regulators in Japan have taken a major misstep in approving a not-ready-for-primetime mesenchymal stem cell (MSC)-based approach to spinal cord injury. Their decision is dangerous and unwise. In a Nature piece (linked to above) by David Cyranoski …

Japan’s dangerous gamble approving unproven stem cells for spinal cord injury Read More »

Launch of Jun Takahashi IPS Cell Trial For Parkinson’s Disease

Jun-Takahashi-252x3001

A much-anticipated induced pluripotent stem (IPS) cell trial for Parkinson’s Disease reportedly will soon launch led by Professor Jun Takahashi. The news broke on Yahoo Japan, which included an unusual number of appropriately sober statements regarding the trial, even though it is an exciting trial as well, compared to most media stories on stem cells. …

Launch of Jun Takahashi IPS Cell Trial For Parkinson’s Disease Read More »

My new Cell Stem Cell piece: too much carrot & not enough stick on stem cell oversight

carrot-and-sticks

I have a new Cell Stem Cell piece out today that aims to take stock of today’s stem cell regulatory oversight in the U.S., Japan, and elsewhere including Australia, Canada and India. I use a carrot and stick metaphor for encouraging legit research and taking regulatory action on serious non-compliant activities, respectively. Where is stem cell …

My new Cell Stem Cell piece: too much carrot & not enough stick on stem cell oversight Read More »

Japan stem cell oversight system too lax?

HeartSheet-Japan-system-stem-cell-oversight

The Japan stem cell and regenerative medicine oversight system has been designed to move investigational therapies forward fast, much faster than the systems in other countries such as the U.S. But how well is it working so far? It’s an important question both for that country and more globally as the Japanese system was touted …

Japan stem cell oversight system too lax? Read More »

Cool stem cell papers: antibody reprogramming, organoids, gravity, & more

gut-organoid

The past few weeks have brought some exciting, thought-provoking stem cell papers and developments in the regenerative medicine field. Here’s a list of stem cell papers in the media that struck me as particularly cool along with some other developments in the field. Human Stem Cells Fight Parkinson’s Disease in Monkeys Organoids Reveal Clues to Gut-Brain …

Cool stem cell papers: antibody reprogramming, organoids, gravity, & more Read More »

Important, endangered species in stem cell medicine: the phase III trial

stem-cell-clinical-trial-system

Traditional clinical trials have four phases. Each phase plays an important, unique role in testing whether new drug products are safe and effective as well as how they compare to the standard of care. Today in the stem cell field across the globe, the Phase III is under fire including what some might call friendly …

Important, endangered species in stem cell medicine: the phase III trial Read More »